vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and HIVE Digital Technologies Ltd. (HIVE). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $93.1M, roughly 1.9× HIVE Digital Technologies Ltd.). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -98.1%, a 97.4% gap on every dollar of revenue. On growth, HIVE Digital Technologies Ltd. posted the faster year-over-year revenue change (218.6% vs 0.7%). Over the past eight quarters, HIVE Digital Technologies Ltd.'s revenue compounded faster (102.2% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Mastech Digital, Inc. is a digital transformation and information technology (IT) services company headquartered in Pittsburgh, Pennsylvania, providing services to corporations across North America, Middle East, Asian, and Japan.
AVNS vs HIVE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $93.1M |
| Net Profit | $-1.3M | $-91.3M |
| Gross Margin | 47.5% | -27.1% |
| Operating Margin | 1.4% | — |
| Net Margin | -0.7% | -98.1% |
| Revenue YoY | 0.7% | 218.6% |
| Net Profit YoY | 99.7% | -234.0% |
| EPS (diluted) | $-0.02 | $-0.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $93.1M | ||
| Q3 25 | $177.8M | $87.3M | ||
| Q2 25 | $175.0M | $45.6M | ||
| Q1 25 | $167.5M | — | ||
| Q4 24 | $179.6M | $29.2M | ||
| Q3 24 | $170.4M | $22.6M | ||
| Q2 24 | $171.7M | $32.2M | ||
| Q1 24 | $166.1M | — |
| Q4 25 | $-1.3M | $-91.3M | ||
| Q3 25 | $-1.4M | $-15.8M | ||
| Q2 25 | $-76.8M | $35.0M | ||
| Q1 25 | $6.6M | — | ||
| Q4 24 | $-397.3M | $68.2M | ||
| Q3 24 | $4.3M | $80.0K | ||
| Q2 24 | $1.8M | $-18.3M | ||
| Q1 24 | $-900.0K | — |
| Q4 25 | 47.5% | -27.1% | ||
| Q3 25 | 48.4% | 4.7% | ||
| Q2 25 | 52.6% | -13.6% | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | -43.7% | ||
| Q3 24 | 54.5% | -66.1% | ||
| Q2 24 | 55.7% | -7.4% | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | -42.6% | — | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | -233.0% | — | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | 2.4% | — |
| Q4 25 | -0.7% | -98.1% | ||
| Q3 25 | -0.8% | -18.1% | ||
| Q2 25 | -43.9% | 76.8% | ||
| Q1 25 | 3.9% | — | ||
| Q4 24 | -221.2% | 233.2% | ||
| Q3 24 | 2.5% | 0.4% | ||
| Q2 24 | 1.0% | -56.7% | ||
| Q1 24 | -0.5% | — |
| Q4 25 | $-0.02 | $-0.38 | ||
| Q3 25 | $-0.03 | $-0.07 | ||
| Q2 25 | $-1.66 | $0.18 | ||
| Q1 25 | $0.14 | — | ||
| Q4 24 | $-8.64 | $0.52 | ||
| Q3 24 | $0.09 | $0.00 | ||
| Q2 24 | $0.04 | $-0.17 | ||
| Q1 24 | $-0.02 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | — |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $559.3M |
| Total Assets | $1.1B | $624.0M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | — | ||
| Q3 25 | $70.5M | — | ||
| Q2 25 | $90.3M | — | ||
| Q1 25 | $97.0M | — | ||
| Q4 24 | $107.7M | $40.5M | ||
| Q3 24 | $89.0M | $31.7M | ||
| Q2 24 | $92.2M | — | ||
| Q1 24 | $75.8M | — |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $559.3M | ||
| Q3 25 | $778.0M | $624.6M | ||
| Q2 25 | $776.3M | $560.5M | ||
| Q1 25 | $839.4M | — | ||
| Q4 24 | $828.5M | $430.9M | ||
| Q3 24 | $1.2B | $275.5M | ||
| Q2 24 | $1.2B | $268.6M | ||
| Q1 24 | $1.2B | — |
| Q4 25 | $1.1B | $624.0M | ||
| Q3 25 | $1.1B | $693.0M | ||
| Q2 25 | $1.0B | $628.7M | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.2B | $478.6M | ||
| Q3 24 | $1.7B | $334.7M | ||
| Q2 24 | $1.7B | — | ||
| Q1 24 | $1.7B | — |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $46.0M |
| Free Cash FlowOCF − Capex | $21.3M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 3.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $46.0M | ||
| Q3 25 | $14.0M | $-10.6M | ||
| Q2 25 | $6.8M | $10.2M | ||
| Q1 25 | $25.7M | — | ||
| Q4 24 | $57.9M | $-28.5M | ||
| Q3 24 | $23.0M | $-2.2M | ||
| Q2 24 | $27.8M | $-4.4M | ||
| Q1 24 | $-8.0M | — |
| Q4 25 | $21.3M | — | ||
| Q3 25 | $7.0M | — | ||
| Q2 25 | $-4.2M | — | ||
| Q1 25 | $19.0M | — | ||
| Q4 24 | $53.1M | $-55.5M | ||
| Q3 24 | $20.0M | $-34.7M | ||
| Q2 24 | $21.9M | — | ||
| Q1 24 | $-12.1M | — |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | -2.4% | — | ||
| Q1 25 | 11.3% | — | ||
| Q4 24 | 29.6% | -189.9% | ||
| Q3 24 | 11.7% | -153.4% | ||
| Q2 24 | 12.8% | — | ||
| Q1 24 | -7.3% | — |
| Q4 25 | 3.8% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 6.3% | — | ||
| Q1 25 | 4.0% | — | ||
| Q4 24 | 2.7% | 92.5% | ||
| Q3 24 | 1.8% | 143.9% | ||
| Q2 24 | 3.4% | — | ||
| Q1 24 | 2.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | -0.42× | ||
| Q3 24 | 5.35× | -26.94× | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
HIVE
Segment breakdown not available.
